trial

Efficacy Study of GAÏA Program Cognitive Remediation of Facial Affects Processing in Schizophrenia

NCTId NCT02110771
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 33 (actual)
Sponsored by Hôpital le Vinatier
Primary completion 2015-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
33 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2012-05
Primary completion
2015-10
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
GAÏA - facial affect recognition targetedRECOS - attentional process targeted

Sponsors

Hôpital le VinatierLead Sponsor
Hospital Center Alpes-IsèreCollaborator
Centre Hospitalier St AnneCollaborator
Centre Hospitalier Intercommunal Clermont de l'OiseCollaborator

Investigators

1
Franck Nicolas, PUPHPrincipal Investigator

Sites

1 total
Lyon, France

Facts & assertions

4 sourced
Enrollment
33
Phase
NA
Primary Completion Date
2015-10
Status
COMPLETED
relationships
The graph out of here
drug
GAÏA - facial affect recognition targeted
drug
RECOS - attentional process targeted
drug
lead_sponsor
Hôpital le Vinatier
company
collaborator
Hospital Center Alpes-Isère
company
Centre Hospitalier St Anne
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Franck Nicolas, PUPH
person